Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen Patterson

Showing results (31-40 of 58) with videos related to

Pageof 6
Sort By:
Plos Pathogens|November 5, 2016
Activation of Bicyclic Nitro-drugs by a Novel Nitroreductase (NTR2) in LeishmaniaSusan Wyllie, Adam J Roberts, Suzanne Norval, et al.
Science Translational Medicine|February 4, 2012
The anti-trypanosome drug fexinidazole shows potential for treating visceral leishmaniasisSusan Wyllie, Stephen Patterson, Laste Stojanovski, et al.
Chemmedchem|June 27, 2009
Synthesis and evaluation of 1-(1-(Benzo[b]thiophen-2-yl)cyclohexyl)piperidine (BTCP) analogues as inhibitors of trypanothione reductaseStephen Patterson, Deuan C Jones, Emma J Shanks, et al.
Sports Medicine (Auckland, N.Z.)|October 3, 2023
Optimising the Early-Stage Rehabilitation Process Post-ACL ReconstructionMatthew Buckthorpe, Alli Gokeler, Lee Herrington, et al.
Elife|May 25, 2016
The anti-tubercular drug delamanid as a potential oral treatment for visceral leishmaniasisStephen Patterson, Susan Wyllie, Suzanne Norval, et al.
ACS Infectious Diseases|June 3, 2025
The Thienopyrimidinone Gamhépathiopine Targets the Q<sub>O</sub> Site of <i>Plasmodium falciparum</i> Cytochrome <i>b</i>Natalie Wiedemar, Rachel Milne, Sandra Carvalho, et al.
Journal of Medicinal Chemistry|August 20, 2011
Dihydroquinazolines as a novel class of Trypanosoma brucei trypanothione reductase inhibitors: discovery, synthesis, and characterization of their binding mode by protein crystallographyStephen Patterson, Magnus S Alphey, Deuan C Jones, et al.
Mbio|August 27, 2024
ResMAP-a saturation mutagenesis platform enabling parallel profiling of target-specific resistance-conferring mutations in <i>Plasmodium</i>Richard J Wall, Stuart A MacGowan, Irene Hallyburton, et al.
Antimicrobial Agents and Chemotherapy|July 17, 2013
The R enantiomer of the antitubercular drug PA-824 as a potential oral treatment for visceral LeishmaniasisStephen Patterson, Susan Wyllie, Laste Stojanovski, et al.
Sports Medicine (Auckland, N.Z.)|December 27, 2025
Force and Power Testing During Anterior Cruciate Ligament Reconstruction Rehabilitation: A World-Wide Survey of Current PracticesAlessandro Compagnin, Francesco Della Villa, Giovanni La Rosa, et al.
Pageof 6

Showing results (31-40 of 58) with videos related to

Sort By:
Pageof 6
Plos Pathogens|November 5, 2016
Activation of Bicyclic Nitro-drugs by a Novel Nitroreductase (NTR2) in LeishmaniaSusan Wyllie, Adam J Roberts, Suzanne Norval, et al.
Science Translational Medicine|February 4, 2012
The anti-trypanosome drug fexinidazole shows potential for treating visceral leishmaniasisSusan Wyllie, Stephen Patterson, Laste Stojanovski, et al.
Chemmedchem|June 27, 2009
Synthesis and evaluation of 1-(1-(Benzo[b]thiophen-2-yl)cyclohexyl)piperidine (BTCP) analogues as inhibitors of trypanothione reductaseStephen Patterson, Deuan C Jones, Emma J Shanks, et al.
Sports Medicine (Auckland, N.Z.)|October 3, 2023
Optimising the Early-Stage Rehabilitation Process Post-ACL ReconstructionMatthew Buckthorpe, Alli Gokeler, Lee Herrington, et al.
Elife|May 25, 2016
The anti-tubercular drug delamanid as a potential oral treatment for visceral leishmaniasisStephen Patterson, Susan Wyllie, Suzanne Norval, et al.
ACS Infectious Diseases|June 3, 2025
The Thienopyrimidinone Gamhépathiopine Targets the Q<sub>O</sub> Site of <i>Plasmodium falciparum</i> Cytochrome <i>b</i>Natalie Wiedemar, Rachel Milne, Sandra Carvalho, et al.
Journal of Medicinal Chemistry|August 20, 2011
Dihydroquinazolines as a novel class of Trypanosoma brucei trypanothione reductase inhibitors: discovery, synthesis, and characterization of their binding mode by protein crystallographyStephen Patterson, Magnus S Alphey, Deuan C Jones, et al.
Mbio|August 27, 2024
ResMAP-a saturation mutagenesis platform enabling parallel profiling of target-specific resistance-conferring mutations in <i>Plasmodium</i>Richard J Wall, Stuart A MacGowan, Irene Hallyburton, et al.
Antimicrobial Agents and Chemotherapy|July 17, 2013
The R enantiomer of the antitubercular drug PA-824 as a potential oral treatment for visceral LeishmaniasisStephen Patterson, Susan Wyllie, Laste Stojanovski, et al.
Sports Medicine (Auckland, N.Z.)|December 27, 2025
Force and Power Testing During Anterior Cruciate Ligament Reconstruction Rehabilitation: A World-Wide Survey of Current PracticesAlessandro Compagnin, Francesco Della Villa, Giovanni La Rosa, et al.
Pageof 6